Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.5507/bp.2014.035 |
| Field | Oncology and hematology |
| Keywords | multiple myeloma; minimal residual disease; tumor-specific marker; ASO PCR; RQ-PCR; IgH gene rearrangement |
| Description | Aim. Multiple myeloma (MM) is a malignant lymphoproliferative disease of terminally differentiated B lymphocytes, characterized by expansion of monoclonal plasma cells. It is the second most common hematological cancer in the world. The introduction of novel drugs is slowly turning MM into a chronic disease. The aim of treatment is hematological remission and eradication of clinical manifestation. Nevertheless, most MM patients eventually relapse. For this reason, research is focused on more accurate monitoring of remission and relapse by molecular biology techniques. One of these techniques is allele-specific PCR and quantitative real-time PCR based on specific detection of VDJ immunoglobulin heavy chain gene rearrangement of clonal cells. The hypervariable region of IgH rearrangement is used as a marker for detection of minimal residual disease (MRD) in MM as this sequence is used for allele-specific primers and probe design. This technique is a complementary tool for flow cytometry in MRD detection in MM. The aim of this study was to introduce detection of MRD by PCR in the Czech Republic. Results. We successfully introduced qualitative and quantitative detection of a tumor marker for MRD assessment of MM by PCR in our laboratory. |
| Related projects: |
|